+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 14Years - 40Years
All Genders
ID06699472

Randomized Clinical Trial to Test Trilaciclib with VDCIE Chemotherapy for Preventing Myelosuppression in Ewings Sarcoma Patients Aged 14 to 40

Led by Fudan University · Updated on 2024-11-21

22

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of using Trilaciclib to prevent chemotherapy-related myelosuppression in patients with Ewings sarcoma who have not previously received systemic anti-tumor treatment. This is a phase 2, prospective, randomized, controlled clinical trial focusing on patients aged 14 to 40 years with confirmed Ewings sarcoma. The study compares the use of Trilaciclib combined with standard VDCIE chemotherapy versus chemotherapy alone. Participants will be randomly assigned to one of two groups the experimental group receiving Trilaciclib along with alternating VDCIE chemotherapy every 3 weeks for up to 17 cycles, or the control group receiving only the alternating VDCIE chemotherapy on the same schedule. The chemotherapy regimen includes vincristine, doxorubicin or actinomycin D after a certain cumulative dose, cyclophosphamide, ifosfamide, and etoposide. Trilaciclib is given as an intravenous infusion following chemotherapy administration in the experimental group. Supportive care is allowed in both groups as needed. During the treatment, participants will be monitored for myelosuppression effects such as neutropenia and thrombocytopenia through laboratory tests. The primary outcome measures how long severe neutropenia lasts in the first treatment cycle, with additional outcomes tracking recovery times, incidence of febrile neutropenia, anemia, and serious infections across multiple cycles. The study will also assess event-free survival up to 24 months. Treatment continues until disease progression, unacceptable side effects, or withdrawal. The total study duration includes up to 17 cycles of treatment and follow-up assessments.

CONDITIONS

Brief Title

A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib

Research Team

X

Xin Liu

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here